Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Tirzepatide India: Lilly and Cipla Expand Access to Advanced Diabetes and Obesity Care India may soon see wider access to Tirzepatide, one of the most potent therapies approved for use in people with type 2 diabetes and chronic weight management, as Eli Lilly and Company India recently signed an agreement with Cipla Limited, allowing the pharmaceutical company Cipla to distribute and promote the drug under a second brand name Yurpeak throughout India
Nausea Nausea is the most common GLP-1 side effect
The American Diabetes Association recommends following the 15-15 rule to raise blood sugar
Investigational medications are not available for prescription and should not be obtained through compounding pharmacies, peptide vendors, or direct-to-consumer services outside FDA-approved channels.
US$ 28.26
US$ 21.74
US$ 21.92
US$ 29.84
US$ 28.53
US$ 29.69
US$ 23.80
US$ 24.50
US$ 27.55
